358 Clinical characteristic and natural history of chemotherapy induced dilated cardiomyopathy
Chemotherapy can lead to chemotherapy-induced dilated cardiomyopathy (CI-DCM), recognized as one of the Non-ischaemic Dilated Cardiomyopathy (DCM) phenotypes characterized by worse outcome. Evidences on a direct comparison between idiopathic-DCM (iDCM) and CI-DCM still lack. We included all the cons...
Gespeichert in:
| Veröffentlicht in: | European heart journal supplements 2021-12, Vol.23 (Supplement_G) |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_G |
| container_start_page | |
| container_title | European heart journal supplements |
| container_volume | 23 |
| creator | Lalario, Andrea Del Mestre, Eva Lo Casto, Michele Nuzzi, Vincenzo Cannatà, Antonio |
| description | Chemotherapy can lead to chemotherapy-induced dilated cardiomyopathy (CI-DCM), recognized as one of the Non-ischaemic Dilated Cardiomyopathy (DCM) phenotypes characterized by worse outcome. Evidences on a direct comparison between idiopathic-DCM (iDCM) and CI-DCM still lack. We included all the consecutive patients enrolled in the Trieste Muscle Heart Disease Registry. C-DCM was defined according to current recommendations. Uni- and multivariable analysis and Kaplan-Meier were performed. The primary outcome was all-cause death and the secondary outcomes were cardiac death and a composite of heart failure hospitalization, heart transplantation, ventricular assist-device implantation and major ventricular arrhythmias. The study included 511 patients (499 patients affected by iDCM and 52 patients affected by CI-DCM). Compared to iDCM, CI-DCM patients were older (51 ± 14 years vs. 58 ± 3 years respectively, P |
| doi_str_mv | 10.1093/eurheartj/suab142.024 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_suab142_024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_eurheartj_suab142_024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c934-e49d8d864bb24429552be86afdfee1466c9ac631e53fb65e1cf917fb261443c3</originalsourceid><addsrcrecordid>eNo9kMtKw0AYhQdRsFYfQcgLpJ17k6UUL4WCC124i39m_iFTcikzk0V2gm_qk5hicXUO5xzO4iPkntEVo6VY4xgahJAO6zhCzSRfUS4vyIIpJXNeMHV58pzmG60-rslNjAdKuSgkXZBPoYqfr-9t63tvoM1MAwFMwuBj8iaD3mY9pDHMVTNHQ5iywc0r7IbUYIDjlPnejgZtZn0LaVYDwfqhm4YjpGa6JVcO2oh3Z12St6fH9-1Lvn993m0f9rkphcxRlrawhZZ1zaXkpVK8xkKDsw6RSa1NCUYLhkq4WitkxpVs42qumZTCiCVRf68mDDEGdNUx-A7CVDFanSBV_5CqM6RqhiR-AVMBYrk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>358 Clinical characteristic and natural history of chemotherapy induced dilated cardiomyopathy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lalario, Andrea ; Del Mestre, Eva ; Lo Casto, Michele ; Nuzzi, Vincenzo ; Cannatà, Antonio</creator><creatorcontrib>Lalario, Andrea ; Del Mestre, Eva ; Lo Casto, Michele ; Nuzzi, Vincenzo ; Cannatà, Antonio</creatorcontrib><description>Chemotherapy can lead to chemotherapy-induced dilated cardiomyopathy (CI-DCM), recognized as one of the Non-ischaemic Dilated Cardiomyopathy (DCM) phenotypes characterized by worse outcome. Evidences on a direct comparison between idiopathic-DCM (iDCM) and CI-DCM still lack. We included all the consecutive patients enrolled in the Trieste Muscle Heart Disease Registry. C-DCM was defined according to current recommendations. Uni- and multivariable analysis and Kaplan-Meier were performed. The primary outcome was all-cause death and the secondary outcomes were cardiac death and a composite of heart failure hospitalization, heart transplantation, ventricular assist-device implantation and major ventricular arrhythmias. The study included 511 patients (499 patients affected by iDCM and 52 patients affected by CI-DCM). Compared to iDCM, CI-DCM patients were older (51 ± 14 years vs. 58 ± 3 years respectively, P < 0.001) and had a higher LVEF (35%±10 vs. 32%±9, P = 0.03). CI-DCM patients had a higher incidence of all-cause of death compared to iDCM (36.5% vs. 8.4%, P < 0.001), while the incidence of cardiac death (7% in the CI-DCM group vs. 4% in the iDCM group, P = 0. 232) and of the composite secondary outcome was comparable amongst the two groups. At multivariable analysis, the diagnosis of CI-DCM was an independent predictor of primary outcome incidence (HR: 5.79, 95% CI: 1.83–18.27), P = 0.003, together atrial fibrillation. In a well-selected DCM cohort, patients with a chemotherapic etiology had a higher incidence of all-cause mortality compared to iDCM, while the incidence of cardiac adverse events was comparable among CI-DCM and iDCM.</description><identifier>ISSN: 1520-765X</identifier><identifier>EISSN: 1554-2815</identifier><identifier>DOI: 10.1093/eurheartj/suab142.024</identifier><language>eng</language><ispartof>European heart journal supplements, 2021-12, Vol.23 (Supplement_G)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Lalario, Andrea</creatorcontrib><creatorcontrib>Del Mestre, Eva</creatorcontrib><creatorcontrib>Lo Casto, Michele</creatorcontrib><creatorcontrib>Nuzzi, Vincenzo</creatorcontrib><creatorcontrib>Cannatà, Antonio</creatorcontrib><title>358 Clinical characteristic and natural history of chemotherapy induced dilated cardiomyopathy</title><title>European heart journal supplements</title><description>Chemotherapy can lead to chemotherapy-induced dilated cardiomyopathy (CI-DCM), recognized as one of the Non-ischaemic Dilated Cardiomyopathy (DCM) phenotypes characterized by worse outcome. Evidences on a direct comparison between idiopathic-DCM (iDCM) and CI-DCM still lack. We included all the consecutive patients enrolled in the Trieste Muscle Heart Disease Registry. C-DCM was defined according to current recommendations. Uni- and multivariable analysis and Kaplan-Meier were performed. The primary outcome was all-cause death and the secondary outcomes were cardiac death and a composite of heart failure hospitalization, heart transplantation, ventricular assist-device implantation and major ventricular arrhythmias. The study included 511 patients (499 patients affected by iDCM and 52 patients affected by CI-DCM). Compared to iDCM, CI-DCM patients were older (51 ± 14 years vs. 58 ± 3 years respectively, P < 0.001) and had a higher LVEF (35%±10 vs. 32%±9, P = 0.03). CI-DCM patients had a higher incidence of all-cause of death compared to iDCM (36.5% vs. 8.4%, P < 0.001), while the incidence of cardiac death (7% in the CI-DCM group vs. 4% in the iDCM group, P = 0. 232) and of the composite secondary outcome was comparable amongst the two groups. At multivariable analysis, the diagnosis of CI-DCM was an independent predictor of primary outcome incidence (HR: 5.79, 95% CI: 1.83–18.27), P = 0.003, together atrial fibrillation. In a well-selected DCM cohort, patients with a chemotherapic etiology had a higher incidence of all-cause mortality compared to iDCM, while the incidence of cardiac adverse events was comparable among CI-DCM and iDCM.</description><issn>1520-765X</issn><issn>1554-2815</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kMtKw0AYhQdRsFYfQcgLpJ17k6UUL4WCC124i39m_iFTcikzk0V2gm_qk5hicXUO5xzO4iPkntEVo6VY4xgahJAO6zhCzSRfUS4vyIIpJXNeMHV58pzmG60-rslNjAdKuSgkXZBPoYqfr-9t63tvoM1MAwFMwuBj8iaD3mY9pDHMVTNHQ5iywc0r7IbUYIDjlPnejgZtZn0LaVYDwfqhm4YjpGa6JVcO2oh3Z12St6fH9-1Lvn993m0f9rkphcxRlrawhZZ1zaXkpVK8xkKDsw6RSa1NCUYLhkq4WitkxpVs42qumZTCiCVRf68mDDEGdNUx-A7CVDFanSBV_5CqM6RqhiR-AVMBYrk</recordid><startdate>20211208</startdate><enddate>20211208</enddate><creator>Lalario, Andrea</creator><creator>Del Mestre, Eva</creator><creator>Lo Casto, Michele</creator><creator>Nuzzi, Vincenzo</creator><creator>Cannatà, Antonio</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211208</creationdate><title>358 Clinical characteristic and natural history of chemotherapy induced dilated cardiomyopathy</title><author>Lalario, Andrea ; Del Mestre, Eva ; Lo Casto, Michele ; Nuzzi, Vincenzo ; Cannatà, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c934-e49d8d864bb24429552be86afdfee1466c9ac631e53fb65e1cf917fb261443c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lalario, Andrea</creatorcontrib><creatorcontrib>Del Mestre, Eva</creatorcontrib><creatorcontrib>Lo Casto, Michele</creatorcontrib><creatorcontrib>Nuzzi, Vincenzo</creatorcontrib><creatorcontrib>Cannatà, Antonio</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal supplements</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lalario, Andrea</au><au>Del Mestre, Eva</au><au>Lo Casto, Michele</au><au>Nuzzi, Vincenzo</au><au>Cannatà, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>358 Clinical characteristic and natural history of chemotherapy induced dilated cardiomyopathy</atitle><jtitle>European heart journal supplements</jtitle><date>2021-12-08</date><risdate>2021</risdate><volume>23</volume><issue>Supplement_G</issue><issn>1520-765X</issn><eissn>1554-2815</eissn><abstract>Chemotherapy can lead to chemotherapy-induced dilated cardiomyopathy (CI-DCM), recognized as one of the Non-ischaemic Dilated Cardiomyopathy (DCM) phenotypes characterized by worse outcome. Evidences on a direct comparison between idiopathic-DCM (iDCM) and CI-DCM still lack. We included all the consecutive patients enrolled in the Trieste Muscle Heart Disease Registry. C-DCM was defined according to current recommendations. Uni- and multivariable analysis and Kaplan-Meier were performed. The primary outcome was all-cause death and the secondary outcomes were cardiac death and a composite of heart failure hospitalization, heart transplantation, ventricular assist-device implantation and major ventricular arrhythmias. The study included 511 patients (499 patients affected by iDCM and 52 patients affected by CI-DCM). Compared to iDCM, CI-DCM patients were older (51 ± 14 years vs. 58 ± 3 years respectively, P < 0.001) and had a higher LVEF (35%±10 vs. 32%±9, P = 0.03). CI-DCM patients had a higher incidence of all-cause of death compared to iDCM (36.5% vs. 8.4%, P < 0.001), while the incidence of cardiac death (7% in the CI-DCM group vs. 4% in the iDCM group, P = 0. 232) and of the composite secondary outcome was comparable amongst the two groups. At multivariable analysis, the diagnosis of CI-DCM was an independent predictor of primary outcome incidence (HR: 5.79, 95% CI: 1.83–18.27), P = 0.003, together atrial fibrillation. In a well-selected DCM cohort, patients with a chemotherapic etiology had a higher incidence of all-cause mortality compared to iDCM, while the incidence of cardiac adverse events was comparable among CI-DCM and iDCM.</abstract><doi>10.1093/eurheartj/suab142.024</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-765X |
| ispartof | European heart journal supplements, 2021-12, Vol.23 (Supplement_G) |
| issn | 1520-765X 1554-2815 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_eurheartj_suab142_024 |
| source | Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | 358 Clinical characteristic and natural history of chemotherapy induced dilated cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T05%3A00%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=358%E2%80%83Clinical%20characteristic%20and%20natural%20history%20of%20chemotherapy%20induced%20dilated%20cardiomyopathy&rft.jtitle=European%20heart%20journal%20supplements&rft.au=Lalario,%20Andrea&rft.date=2021-12-08&rft.volume=23&rft.issue=Supplement_G&rft.issn=1520-765X&rft.eissn=1554-2815&rft_id=info:doi/10.1093/eurheartj/suab142.024&rft_dat=%3Ccrossref%3E10_1093_eurheartj_suab142_024%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |